All In Biotech

Drug Trial Radar · NCT01892137

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

137

Actual

Start

Jul 2013

Primary completion

Mar 2014

Study completion May 2014

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jul 4, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this trial is to demonstrate the predictive value of the clinical diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using histopathological examination as the standard.

Conditions

  • Actinic Keratosis

Interventions

  • Ingenol mebutate gel 0.05%Drug

    Once daily for 2 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clearance of AKTime frame: 8 weeks

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Southderm Pty Ltd

    Kogarah, New South Wales, Australia

  • Melanoma Institute Australia

    North Sydney, New South Wales, Australia

  • The Skin Centre

    Benowa, Queensland, Australia

  • South East Dermatology Centre

    Carina Heights, Queensland, Australia

  • St John of God Dermatology

    Subiaco, Western Australia, Australia

  • Burswood Dermatology

    Victoria Park, Western Australia, Australia

  • Klinik für Dermatologie & Allergologie Klinikum Augsburg Süd

    Augsburg, Germany

  • Collegium Medicum Berlin GmbH

    Berlin, Germany

  • Medizinisches Zentrum Bonn Friedensplatz

    Bonn, Germany

  • Hautarztpraxis Prof. Dr. med. C. Termeer

    Stuttgart, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.